Arcellx (ACLX) Share-based Compensation (2021 - 2025)
Arcellx's quarterly Share-based Compensation came in at $18.1 million in Q4 2025, up 14.6% year-on-year from $15.8 million in Q4 2024, and up 0.8% quarter-over-quarter from $17.9 million in Q3 2025.
Arcellx has reported Share-based Compensation for 5 years, with the latest figure at $18.1 million in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation rose 14.6% year-over-year to $18.1 million; the trailing twelve-month figure through Dec 2025 stood at $77.9 million (up 27.51% YoY), and the FY2025 full-year result was $77.9 million, up 27.51% from the prior year.
- Share-based Compensation for Q4 2025 stood at $18.1 million, up from $17.9 million in the prior quarter.
- The five-year high for Share-based Compensation was $23.8 million in Q1 2025, with the low at $757000.0 in Q1 2021.
- Average Share-based Compensation over 5 years is $10.5 million, with a median of $10.5 million recorded in 2023.
- Year-over-year, Share-based Compensation surged 491.94% in 2022 and climbed 14.6% in 2025.
- Tracing ACLX's Share-based Compensation over 5 years: stood at $2.9 million in 2021, then surged by 99.52% to $5.8 million in 2022, then jumped by 83.33% to $10.6 million in 2023, then surged by 48.55% to $15.8 million in 2024, then rose by 14.6% to $18.1 million in 2025.
- The last three Share-based Compensation figures came in at $18.1 million (Q4 2025), $17.9 million (Q3 2025), and $18.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 18.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.07 Mn |
| Dec 31, 2025 | 18.07 Mn |
| Sep 30, 2025 | 17.93 Mn |
| Sep 30, 2025 | 17.93 Mn |
| Jun 30, 2025 | 18.08 Mn |
| Jun 30, 2025 | 18.08 Mn |
| Mar 31, 2025 | 23.82 Mn |
| Mar 31, 2025 | 23.82 Mn |
| Dec 31, 2024 | 15.77 Mn |
| Dec 31, 2024 | 15.77 Mn |
| Sep 30, 2024 | 15.33 Mn |
| Sep 30, 2024 | 15.33 Mn |
| Jun 30, 2024 | 15.14 Mn |
| Jun 30, 2024 | 15.14 Mn |
| Mar 31, 2024 | 14.85 Mn |
| Mar 31, 2024 | 14.85 Mn |
| Dec 31, 2023 | 10.62 Mn |
| Dec 31, 2023 | 10.62 Mn |
| Sep 30, 2023 | 10.61 Mn |
| Sep 30, 2023 | 10.61 Mn |
| Jun 30, 2023 | 10.40 Mn |
| Jun 30, 2023 | 10.40 Mn |
| Mar 31, 2023 | 10.16 Mn |
| Mar 31, 2023 | 10.16 Mn |
| Dec 31, 2022 | 5.79 Mn |
| Dec 31, 2022 | 5.79 Mn |
| Sep 30, 2022 | 5.33 Mn |
| Sep 30, 2022 | 5.33 Mn |
| Jun 30, 2022 | 5.94 Mn |
| Jun 30, 2022 | 5.94 Mn |
| Mar 31, 2022 | 4.48 Mn |
| Mar 31, 2022 | 4.48 Mn |
| Dec 31, 2021 | 2.90 Mn |
| Dec 31, 2021 | 2.90 Mn |
| Sep 30, 2021 | 1.90 Mn |
| Sep 30, 2021 | 1.90 Mn |
| Jun 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 1.20 Mn |
| Mar 31, 2021 | 757,000.00 |
| Mar 31, 2021 | 757,000.00 |